IGF2BP2 and METTL3 competitively bind miR-93-5p to promote CCND1 expression, enhancing cancer cell proliferation, migration, and angiogenesis, while also inhibiting PDCD4 to facilitate cell cycle progression. The gene discussed is METTL3; the disease is cancer.